Allied CORP

Calum Hughes resigned as Chief Executive Officer and a Director of Allied Corp., effective January 30, 2025.

Allied Corp has announced its decision to voluntarily cease trading on the OTCQB and terminate its SEC registration to redirect resources towards growth initiatives.

Allied Corp. has successfully shipped 30kg of medical cannabis to its Portuguese partner, marking the start of a UK supply contract expected to generate at least $360,000 in annual revenue.

Allied Corp.'s subsidiary, Allied Colombia S.A.S., has entered into a five-year forward purchase agreement to supply medical-grade cannabis to CanPoland for distribution in Poland.

Allied Corp. has successfully released its first GMP-certified medical cannabis product into the Swiss market, marking a significant milestone for the company.

Allied Corp. reports the departure of Chief Financial Officer, Ryan Maarschalk, effective August 19, 2024.

Allied Corp. reported a net loss of $780,290 for the quarter ended November 30, 2024, a slight improvement compared to the same period last year, while facing continued going concern challenges.

Allied Corp. reported a revenue increase in Q3 2024, but also a net loss and a working capital deficit, raising concerns about its ability to continue as a going concern.

Allied Corp. faces continued financial strain, reporting a $1.7 million net loss in the second quarter of 2024, raising substantial doubt about its ability to continue as a going concern.

Allied Corp. reports a net loss of $836,673 for the quarter ended November 30, 2023, with a significant decrease in revenue compared to the same period last year.

Allied Corp.'s amended 10-K filing details its focus on Colombian cannabis production, commercial expansion, and strategic shifts away from US operations and clinical trials.

Allied Corp. reports its fiscal year 2024 results, highlighting a strategic shift towards international cannabis production and distribution, particularly in Colombia, while temporarily pausing other initiatives.